Abstract
Dapagliflozin belongs to a new class of drugs used for the treatment of heart failure — sodium-glucose cotransporter type 2 inhibitors (SGLT2i). Based on the DAPA-HF study results, dapagliflozin has become the first SGLT2i approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction. The present review summarizes the most important clinical issues related to the treatment with this drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
